Abstract
Lysophosphatidic acid (LPA) is present during the medical condition of ovarian cancer at all stages of the disease, and, therefore possesses considerable potential as a biomarker for screening its presence in female patients. Unfortunately, there is currently no clinically employable assay for this biomarker. In the present work, we introduce a test based on the duel protein system of actin and gelsolin that could allow the quantitative measurement of LPA in serum samples in a biosensing format. In order to evaluate this possibility, actin protein was dye-modified and complexed with gelsolin protein, followed by surface deposition onto silica nanoparticles. This solid-phase system was exposed to serum samples containing various concentrations of LPA and analyzed by fluorescence microscopy. Measurements conducted for the LPA-containing serum samples were higher after exposure to the developed test than samples without LPA. Early results suggest a limit of detection of 5 μM LPA in serum. The eventual goal is to employ the chemistry described here in a biosensor configuration for the large population-scale, rapid screening of women for the potential occurrence of ovarian cancer.
Highlights
A patent has been filed on the technology developed in this paper, along with the methods of its production; patent application number PCT/CA2016/050545, and US 15/572,295 by Brian De La Franier and Michael Thompson [1].In women over 50 years of age, cancers are one of the leading causes of death at over 15% of the population [2,3]
We examined the chemistry of the actin–gelsolin combination for the detection of this fluorescence work, we examined the chemistry of the gelsolin actin–gelsolin combination theactin detection of Lysophosphatidic acid (LPA) In using spectroscopy
In order to to function properly, the modified actin actin must still ablebe to able bind to to gelsolin, gelsolin, and this binding must be reversed in the presence of
Summary
A patent has been filed on the technology developed in this paper, along with the methods of its production; patent application number PCT/CA2016/050545, and US 15/572,295 by Brian De La Franier and Michael Thompson [1].In women over 50 years of age, cancers are one of the leading causes of death at over 15% of the population [2,3]. Though ovarian cancer is less common than several other female cancers, such as breast cancer, it displays the highest fatality-to-case ratio of all gynecological cancers, rendering it a very serious issue, especially for post-menopausal women [4,5,6,7,8]. This is reflected in the poor five-year survival rate of 25% for women diagnosed at a late stage of the disease, versus those diagnosed in stages I or II, which is over. This data clearly implies that there is a critical need to improve diagnosis in the early stages of the disease in order to significantly increase the survival rate for those women who suffer from the disease
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
